相关实验视频
Updated: May 5, 2026

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
25.3K
甲福明和2型糖尿病患者的认知表现:一个总体审查
Athena Enderami1, Behnam Shariati2, Mehran Zarghami3
1Department of Psychiatry, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Neuropsychopharmacology reports
|January 28, 2025
概括
甲胺可能为2型糖尿病患者提供认知效益,可能改善记忆力并降低神经退行性疾病风险. 然而,目前的证据质量很低,需要对其认知影响进行进一步的研究.
科学领域:
- 内分泌学 在内分泌学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 关于甲福明对2型糖尿病 (T2DM) 认知功能的影响,存在矛盾的发现.
- 甲胺是用于T2DM管理的广泛使用的药物.
- 了解其神经效应对于患者护理至关重要.
研究的目的:
- 系统地审查和分析现有证据,以了解甲福明在T2DM患者认知表现中的作用.
- 评估现有证据的质量.
- 确定甲胺对认知的潜在益处或风险.
主要方法:
- 在多个数据库 (PubMed, Web of Science, Scopus, Cochrane Library, Trip, Google Scholar) 进行了全面的文献搜索,截至2023年5月1日.
- 包括英语撰写的系统评论和元分析.
- 从2672个初始记录中确定了10项相关研究.
主要成果:
- 有证据表明,甲福明可能会带来认知效益,包括潜在的记忆改善和降低神经退行性疾病的风险.
- 在迷你心理状态考试 (MMSE) 和选择性提醒测试 (SRT) 成绩中也出现了改善.
- 阿尔茨海默病评估尺度-认知子尺度 (ADAS-Cog) 的改变引发了一些担忧,表明对认知领域的差异性影响.
结论:
- 甲福明可能对T2DM患者的特定认知功能产生积极影响.
- 目前的证据基础以不一致性和低质量为特征.
- 需要进一步进行高质量的研究,以澄清甲胺在T2DM相关的认知变化中的确切作用 (保护性,中性或上下文依赖).
相关概念视频
Carbohydrate Metabolism
10.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
Oral Hypoglycemic Agents: Biguanides and Glitazones
164
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
164
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
148
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
148

